ArticleActa pharmaceutica Sinica. B2023
Discovery and identification of EIF2AK2 as a direct key target of berberine for anti-inflammatory effects.
Article in Acta pharmaceutica Sinica. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 81 citations in OpenAlex.
- Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Berberine Attenuates Hepatic Sinusoidal Obstruction Syndrome by Inhibiting Endothelial-mediated Neutrophil Recruitment and Activation.Journal of clinical and translational hepatology · 2026Article
- Structure-Activity Relationship Study of Protoberberine Alkaloids Reveals Molecular Planarity as a Key Determinant of Membrane Interaction and Protection from Misfolded Protein Oligomers.Journal of medicinal chemistry · 2026Article
- The integrated analysis of PRDX3 in lung cancer: biomarker potential and therapeutic target prospects.Respiratory research · 2026Article
- Curcumin ameliorates metabolic dysfunction-associated steatotic liver diseaseActa pharmaceutica Sinica. B · 2026Article
- Natural Product-Derived Activity-Based and Affinity-Based Probes: Tools for Mechanism of Action Studies.Molecules (Basel, Switzerland) · 2026Review
- Berberine: A Negentropic Modulator for Multi-System Coordination.International journal of molecular sciences · 2026Review
- A Janus bacterial cellulose patch with antibacterial, antioxidant, anti-inflammatory and angiogenic activities for enhanced oral ulcer healing.Regenerative biomaterials · 2026Article
- Advanced applications of synthetic biology technology in biosynthesis of bioactive compounds from medicinal plants.Chinese herbal medicines · 2026Review
- Nanomedicine-enabled neuroprotection: therapeutic role of berberine in neurodegenerative diseases.Molecular biology reports · 2025Review
- Target discovery-directed pharmacological mechanism elucidation of bioactive natural products.Medical review (2021) · 2025Review
- Identification of differentially expressed immune-related genes in patients with systemic lupus erythematosus and the development of a hub gene-based diagnostic model.European journal of medical research · 2025Article
- Common mechanisms of Gut microbe-based strategies for the treatment of intestine-related diseases: based on multi-target interactions with the intestinal barrier.Cell communication and signaling : CCS · 2025Review
- Mechanistic Study on the Alleviation of Endometritis in Mice Through Inhibition of NF-κB and MAPK Signaling Pathways by Berberine and Carvacrol.Microorganisms · 2025Article
- Identifying and validating immunological biomarkers in obstructive sleep apnea through bioinformatics analysis.Scientific reports · 2025Article
- Multi-Omics and Network-Based Drug Repurposing for Septic Cardiomyopathy.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Heart Failure Is Closely Associated With the Expression Characteristics of Type I Interferon-Related Genes.Clinical cardiology · 2025Article
- Berberine and its derivatives: mechanisms of action in myocardial vascular endothelial injury - a review.Frontiers in pharmacology · 2025Review
- The potential value of the use of berberine in depression: a systematic review and meta-analysis of preclinical studies.Frontiers in pharmacology · 2025Article
- Efficacy and safety of Shengjiang Xiexin decoction on irinotecan-induced diarrhea in small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial.Chinese medicine · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
16 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Using chemoproteomic techniques, we first identified EIF2AK2, eEF1A1, PRDX3 and VPS4B as direct targets of berberine (BBR) for its synergistically anti-inflammatory effects. Of them, BBR has the strongest affinity with EIF2AK2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.